Immunocore and Pulse Infoframe announced a partnership to support a global patient registry in uveal melanoma, according to a press release.
Institutions from the United States, the United Kingdom and Australia will participate in the registry, which will examine risk factors, genetics, epidemiology, treatment cost-effectiveness and real-world outcomes.
“We’re excited to be working with the research community to address the need for a more comprehensive understanding of uveal melanoma,” Mohammed Dar, MD, head of clinical development and chief medical officer at Immunocore, said in the release. “We believe that this registry will provide critical insight that may help to advance the development of future treatments, including clinical and genetic information about potential subsets of people living with this devastating disease.”
Enrollment in the registry is expected to begin in August.